BBP: VIRTUS BIOTECH ETF
Understanding the VIRTUS BIOTECH ETF (BBP)
The VIRTUS BIOTECH ETF (ticker: BBP) is an exchange-traded fund that focuses on the biotechnology sector. This ETF provides investors with exposure to various companies working in biotech research and medicine.
What this ETF is trying to do
BBP invests in a collection of biotechnology companies. Based on its top holdings, the fund includes companies like Moderna Inc (4.71%) and Iovance Biotherapeutics Inc (3.22%). Because it holds many different companies, it spreads its investment across the biotech industry rather than relying on just one stock.
What the numbers show
The performance data for BBP shows significant growth in share prices over different time periods. It is important to note that "price return" refers only to the change in the share price.
• Year-to-Date (YTD) Price Return: Approximately 28.26%
• One-Year Price Return: Approximately 43.62%
• Three-Year Price Return: Approximately 109.74%
• Five-Year Total Return: Approximately 102.11%
For this ETF, the YTD, one-year, and three-year price returns are the same as the total returns provided in the data. This is because no distributions were detected during these periods.
An estimated price from roughly one year ago was $71.37. The current price is $102.50.
Income and distribution explanation
Some investors look for ETFs that pay regular cash, known as distributions. For BBP, no distributions were detected over the last 12 months. The distribution yield is 0%, and there has been no payout frequency recorded.
NAV erosion explanation
"NAV erosion" refers to a decline in the Net Asset Value (the actual value of the assets held by the fund). While a falling share price can sometimes be a sign of trouble, it does not always mean the NAV is eroding.
For BBP, the erosion-risk score is 100, which is labeled as "No price erosion detected." The erosion severity is rated as "good," and there is no severe erosion-risk flag. The supplied data is sufficient to evaluate price erosion, but it does not include enough historical NAV-per-share data to confirm or rule out NAV erosion.
Pros
• Strong Price Growth: The fund has shown high price returns over the last one, three, and five years.
• Low Erosion Risk: The data shows no detected price erosion.
Cons
• No Income: This ETF does not currently provide cash distributions or a dividend yield.
• Sector Focus: Because it focuses on biotechnology, its performance is tied to that specific industry.
Beginner takeaway
BBP is an ETF that has experienced strong share-price growth recently. It is a growth-focused fund rather than an income-focused fund, as it does not currently pay out distributions to investors. Always remember that holdings can change over time.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | MODERNA INC | MRNA | 4.71% |
| 2 | IOVANCE BIOTHERAPEUTICS INC | IOVA | 3.22% |
| 3 | OMEROS CORP | OMER | 3.06% |
| 4 | VERASTEM INC | VSTM | 2.58% |
| 5 | PRECIGEN INC | PGEN | 2.16% |
| 6 | HALOZYME THERAPEUTICS INC | HALO | 2.09% |
| 7 | ZAI LAB LTD ADR REPR 1 SHS | ZLAB | 2.00% |
| 8 | n/a | KNSA | 1.89% |
| 9 | RIGEL PHARMACEUTICALS INC | RIGL | 1.89% |
| 10 | BEONE MEDICINES LTD ADR | ONC | 1.78% |